Henri Deda

Posts by henri.deda


Kai Simons, founder and CEO of Lipotype, has been following the development of omic science for decades. His lifelong experience as well as his proficiency in lipids and lipidomics has led him to a detailed review.

The published article “How can Omic Science be improved?” critically analyzes the shortcomings of modern omic science, which yet could not fulfill its promise of a paradigm shift in medicine and biology. Bot, scientific evolution and present challenges of this field of research are taken into account to picture the overall view.

While the article itself focuses on lipidomics, Kai Simon’s field of expertise, all lessons learned can be applied generally to omic science.

Read the full article here:
How can Omic Science be improved? – Proteomics Journal, 2018
Kai Simons

Recent Lipidomics News: Always stay on top of lipids!

Our news channels feature recent developments in lipidomics including skin, food, pharma/biotech and academic research. Challenging thoughts on how to apply lipidomics and the most important conventions, as well as scientific publications and cutting-edge research can be found there.

Follow our news channels to always stay on top of lipids!

Follow us on:
LinkedIn, Facebook and Twitter, and check our News Section regularly to stay lipidomics-updated!

Lipids in diabetes type 2 research

The Paul Langerhans Institute Dresden (PLID) tackles diabetes by applying lipidomics analysis form Lipotype.

Lipids and diabetes
The PLID frequently applies Lipotype Shotgun Lipidomics services for their molecular diabetes research to step by step reveal lipid-associated cellular processes. Their investigations lead to the definition of molecular lipid signatures that tell about the development on non-diabetic to diabetes type 2 and progression towards diabetes complications.

Furthermore, the PLID is a project partner of Lipotype within the RHAPSODY consortium, an IMI project combining new and existing data to refine diagnosis, promote prevention and support drug discovery for personalized management of diabetes.

About the PLID
In type 1 and type 2 diabetes, destroyed or impaired beta cells cause an elevated blood sugar level. PLID scientists are working on deciphering the mechanisms that lead to the destruction and/or functional impairment of beta cells and are also trying to develop new approaches to replace damaged or destroyed beta cells.

The PLID is a founding partner of the German Center for Diabetes Research (DZD).


1 – Multi-omics insights into functional alterations of the liver in insulin-deficient diabetes mellitus

Follow us on LinkedIn, Twitter or Facebook, and subscribe to our newsletter to stay updated on lipids and lipidomics!